deferoxamine has been researched along with Retinal Diseases in 33 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine mesylate (DFO) is the most commonly used iron-chelating agent to treat transfusion-related hemosiderosis." | 4.91 | Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature. ( Barteselli, G; Dell'Arti, L; Di Nicola, M; Ratiglia, R; Viola, F, 2015) |
| "A 34-year-old man with thalassemia major complained of nyctalopia and decreased vision following high-dose intravenous deferoxamine to treat systemic iron overload." | 3.80 | Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. ( Chen, YH; Lai, CC; Wu, CH; Wu, WC; Yang, CP, 2014) |
| "Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemochromatosis." | 3.74 | Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. ( Baath, JS; Chun, A; Kirby, M; Lam, WC, 2008) |
| "Deferoxamine is a commonly used chelating agent for secondary hemochromatosis." | 1.46 | Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity. ( Bui, KM; Sadda, SR; Salehi-Had, H, 2017) |
| " In thalassaemic patients, no significant correlations between retinal venous length and, respectively, plasma ferritin level and DFX daily dosage were documented." | 1.32 | Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major. ( Costagliola, C; D'Angelo, S; Incorvaia, C; Parmeggiani, F; Perri, P; Sebastiani, A, 2003) |
| "Two years later she noticed a grey scotoma in her right eye." | 1.32 | EOG as a monitor of desferrioxamine retinal toxicity. ( Goode, DH; Hidajat, RR; McLay, JL; Spearing, RL, 2004) |
| "Deferoxamine has recently been conjugated to certain high molecular weight biocompatible polymers without altering its iron-binding properties." | 1.29 | Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. ( Gehlbach, PL; Hallaway, PE; Hedlund, BE; Purple, RL, 1993) |
| " Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible." | 1.28 | Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. ( Cases, A; Griño, MC; Kelly, J; Lopez-Pedret, J; Revert, L; Sabater, F; Torras, A, 1990) |
| " The incidence of such changes is not related to drug dosage or to ferritin level but to abnormality of the extended glucose tolerance test." | 1.27 | Ocular changes in patients undergoing long-term desferrioxamine treatment. ( Arden, GB; Huehns, ER; Kennedy, C; Wonke, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.12) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bui, KM | 1 |
| Sadda, SR | 1 |
| Salehi-Had, H | 1 |
| Jauregui, R | 1 |
| Park, KS | 1 |
| Bassuk, AG | 1 |
| Mahajan, VB | 1 |
| Tsang, SH | 2 |
| Viola, F | 3 |
| Barteselli, G | 3 |
| DellʼArti, L | 1 |
| Vezzola, D | 2 |
| Mapelli, C | 2 |
| Villani, E | 2 |
| Ratiglia, R | 3 |
| Lamba, N | 1 |
| Anderson-Nelson, S | 1 |
| Wu, CH | 1 |
| Yang, CP | 1 |
| Lai, CC | 1 |
| Wu, WC | 1 |
| Chen, YH | 1 |
| Gelman, R | 1 |
| Kiss, S | 1 |
| Di Nicola, M | 1 |
| Dell'Arti, L | 2 |
| El-Shazly, AA | 1 |
| Ebeid, WM | 1 |
| Elkitkat, RS | 1 |
| Deghedy, MR | 1 |
| Baath, JS | 1 |
| Lam, WC | 1 |
| Kirby, M | 1 |
| Chun, A | 1 |
| Genead, MA | 2 |
| Fishman, GA | 2 |
| Anastasakis, A | 1 |
| Lindeman, M | 1 |
| Zanaboni, L | 1 |
| Cappellini, MD | 1 |
| Simon, S | 1 |
| Athanasiov, PA | 1 |
| Jain, R | 1 |
| Raymond, G | 1 |
| Gilhotra, JS | 1 |
| Incorvaia, C | 1 |
| Parmeggiani, F | 1 |
| Costagliola, C | 1 |
| Perri, P | 1 |
| D'Angelo, S | 1 |
| Sebastiani, A | 1 |
| Schmidt, D | 1 |
| Finke, J | 1 |
| Gonzales, CR | 1 |
| Lin, AP | 1 |
| Engstrom, RE | 1 |
| Kreiger, AE | 1 |
| Arora, A | 1 |
| Wren, S | 1 |
| Gregory Evans, K | 1 |
| Kertes, PJ | 1 |
| Lee, TK | 1 |
| Coupland, SG | 1 |
| Hidajat, RR | 1 |
| McLay, JL | 1 |
| Goode, DH | 1 |
| Spearing, RL | 1 |
| Lai, TY | 1 |
| Lee, GK | 1 |
| Chan, WM | 1 |
| Lam, DS | 1 |
| Reddy, S | 1 |
| Slakter, J | 1 |
| Aaberg, TM | 1 |
| Singh, RP | 1 |
| Kaiser, PK | 1 |
| Arden, GB | 1 |
| Wonke, B | 1 |
| Kennedy, C | 1 |
| Huehns, ER | 1 |
| Gehlbach, PL | 1 |
| Purple, RL | 1 |
| Hallaway, PE | 1 |
| Hedlund, BE | 1 |
| Rinaldi, M | 1 |
| Della Corte, M | 1 |
| Ruocco, V | 1 |
| D'Onofrio, C | 1 |
| Zanotta, G | 1 |
| Romano, A | 1 |
| Albalate, M | 1 |
| Velasco, L | 1 |
| Ortiz, A | 1 |
| Monzú, B | 1 |
| Casado, S | 1 |
| Caramelo, C | 1 |
| Sánchez Dalmau, BF | 1 |
| Vela Payán, MD | 1 |
| Haimovici, R | 1 |
| D'Amico, DJ | 1 |
| Gragoudas, ES | 1 |
| Sokol, S | 1 |
| Cases, A | 1 |
| Kelly, J | 1 |
| Sabater, F | 1 |
| Torras, A | 1 |
| Griño, MC | 1 |
| Lopez-Pedret, J | 1 |
| Revert, L | 1 |
| Sorcinelli, R | 2 |
| Sitzia, A | 2 |
| Figus, A | 1 |
| Lai, ME | 1 |
| Good, PA | 2 |
| Claxson, A | 1 |
| Morris, CJ | 1 |
| Blake, DR | 2 |
| Larricart, P | 1 |
| Pall, H | 1 |
| Winyard, P | 1 |
| Williams, AC | 1 |
| De Virgiliis, S | 1 |
| Congia, M | 1 |
| Turco, MP | 1 |
| Frau, F | 1 |
| Dessi, C | 1 |
| Argiolu, F | 1 |
| Cao, A | 1 |
2 reviews available for deferoxamine and Retinal Diseases
| Article | Year |
|---|---|
Medication induced retinal side effects.
Topics: Antimalarials; Canthaxanthin; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; | 2014 |
Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.
Topics: Deferoxamine; Hemosiderosis; Humans; Iron Chelating Agents; Retina; Retinal Diseases; Retinal Vessel | 2015 |
1 trial available for deferoxamine and Retinal Diseases
| Article | Year |
|---|---|
High risk of retinal damage by desferrioxamine in dialysis patients.
Topics: Antidotes; Deferoxamine; Humans; Renal Dialysis; Retinal Diseases; Risk | 1996 |
30 other studies available for deferoxamine and Retinal Diseases
| Article | Year |
|---|---|
Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.
Topics: Aged; Deferoxamine; Electroretinography; Fluorescein Angiography; Fundus Oculi; Humans; Male; Multim | 2017 |
Deferoxamine-induced electronegative ERG responses.
Topics: Atrophy; Deferoxamine; Electroretinography; Fluorescein Angiography; Humans; Iron Overload; Male; Mi | 2018 |
Multimodal imaging in deferoxamine retinopathy.
Topics: Adult; beta-Thalassemia; Deferoxamine; Female; Fluorescein Angiography; Follow-Up Studies; Humans; M | 2014 |
Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.
Topics: Adult; Deferoxamine; Dose-Response Relationship, Drug; Fluorescein Angiography; Fundus Oculi; Humans | 2014 |
Multimodal imaging in a case of deferoxamine-induced maculopathy.
Topics: beta-Thalassemia; Deferoxamine; Humans; Iron Chelating Agents; Male; Middle Aged; Retinal Diseases; | 2014 |
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA.
Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dos | 2017 |
Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
Topics: Child; Deferoxamine; Female; Hemochromatosis; Humans; Incidence; Iron Chelating Agents; Male; Monito | 2008 |
Macular vitelliform lesion in desferrioxamine-related retinopathy.
Topics: beta-Thalassemia; Deferoxamine; Electroretinography; Female; Fluorescein Angiography; Humans; Middle | 2010 |
Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.
Topics: Carbonic Anhydrase Inhibitors; Deferoxamine; Female; Humans; Macula Lutea; Middle Aged; Ophthalmic S | 2011 |
Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
Topics: Adult; Aged; beta-Thalassemia; Case-Control Studies; Cross-Sectional Studies; Deferoxamine; Female; | 2012 |
Desferrioxamine-related ocular toxicity: a case report.
Topics: Adult; beta-Thalassemia; Deferoxamine; Diagnosis, Differential; Dose-Response Relationship, Drug; El | 2012 |
Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Case-Control Studies; Child; Deferoxamine; Female; | 2003 |
[Bull's-Eye Maculopathy with Deferoxamine Treatment].
Topics: Aged; Anemia; Deferoxamine; Electroretinography; Erythrocyte Transfusion; Ferritins; Fluorescein Ang | 2004 |
Bilateral vitelliform maculopathy and deferoxamine toxicity.
Topics: Aged; Deferoxamine; Female; Fluorescein Angiography; Humans; Iron Chelating Agents; Neural Tube Defe | 2004 |
Desferrioxamine related maculopathy: a case report.
Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl | 2004 |
The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy.
Topics: Aged; Deferoxamine; Drug Monitoring; Electroretinography; Female; Fluorescein Angiography; Humans; I | 2004 |
EOG as a monitor of desferrioxamine retinal toxicity.
Topics: Anemia, Hemolytic, Autoimmune; Deferoxamine; Electrooculography; Female; Humans; Iron Chelating Agen | 2004 |
Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.
Topics: Adolescent; beta-Thalassemia; Deferoxamine; Humans; Male; Retinal Diseases; Siderophores; Visual Acu | 2006 |
Diagnostic and therapeutic challenges.
Topics: Abdominal Pain; Aged; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Glomerulon | 2007 |
Ocular changes in patients undergoing long-term desferrioxamine treatment.
Topics: Adolescent; Adult; Child; Deferoxamine; Electrooculography; Electroretinography; Female; Glucose Tol | 1984 |
Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model.
Topics: Animals; Dark Adaptation; Deferoxamine; Electroretinography; Hydroxyethyl Starch Derivatives; Male; | 1993 |
Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
Topics: Adolescent; Adult; Age Factors; Angioid Streaks; beta-Thalassemia; Cataract; Child; Child, Preschool | 1993 |
[Retinopathy caused by desferrioxamine].
Topics: Aged; Deferoxamine; Female; Humans; Retinal Diseases; Siderophores | 1996 |
The expanded clinical spectrum of deferoxamine retinopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Deferoxamine; Electrooculography; Electroretinography; F | 2002 |
Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
Topics: Adult; Aged; Aged, 80 and over; Aluminum; Chelation Therapy; Deferoxamine; Female; Hearing Loss, Bil | 1990 |
Ocular findings in beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Cataract; Child; Deferoxamine; Eye Diseases; Female; Humans; M | 1990 |
A model for desferrioxamine-induced retinopathy using the albino rat.
Topics: Animals; Dark Adaptation; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; El | 1990 |
[Retinal diseases].
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Antipsychotic Agents; Canthaxanthin; Ca | 1985 |
Copper chelation and the neuro-ophthalmic toxicity of desferrioxamine.
Topics: Chelating Agents; Copper; Deferoxamine; Humans; Retinal Diseases | 1986 |
Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.
Topics: Adolescent; Child; Copper; Deferoxamine; Electroretinography; Humans; Infusions, Intravenous; Retina | 1988 |